Azenta (AZTA) AI Stock Analysis

• Market Cap: $1.40B
• Dividend Yield: N/A
• Average Volume (3M): 664.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -8.15%
• EPS Growth: 13.50%
• Country: US
• Employees: 3,000
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.19
• Shares Outstanding: 45,839,730
• 10 Day Avg. Volume: 539,159
• 30 Day Avg. Volume: 664,122
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 1.89
• Enterprise Value/Gross Profit: 4.20
• Enterprise Value/Ebitda: 31.49
• 1Y Price Target: $34.60
• Price Target Upside: 14.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 48 Neutral
• Price Target: $30.00 ▼(-0.66% Downside)

Azenta's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative profit margins. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to a negative P/E ratio. Despite positive elements from the earnings call, such as margin expansion and growth in specific areas, these are not enough to offset the broader financial and market challenges.

Positive Factors

Margin Improvement

Azenta is expected to achieve margin improvement, which should justify a higher valuation.

Operational Efficiency

Cost-saving and efficiency initiatives under the new management team are showing positive results.

Strategic Partnerships

A new partnership in cell and gene therapy expands Azenta's business portfolio and enhances growth opportunities.

Negative Factors

Geopolitical Risks

China is expected to remain a double-edged sword that could keep Azenta at a higher risk of exposure if geopolitical tensions continue.

Quarterly Results

The recent quarterly results were affected by order delays and missed expectations in certain segments.

Revenue Miss

FQ3 total revs of $144M missed consensus $149M largely due to geo-driven slowdown in both storage and gene synthesis segments.

Azenta Business Overview & Revenue Model

Company Description

Azenta, Inc. (AZTA) is a leading provider of life sciences solutions, focusing on biobanking and laboratory services. The company operates primarily in the biotechnology and pharmaceutical sectors, offering a range of products and services such as sample management, genomic analysis, and data solutions. Azenta's mission is to empower researchers and organizations in the life sciences field by providing innovative solutions that enhance the efficiency and effectiveness of their research processes.

How the Company Makes Money

Azenta generates revenue through multiple streams, primarily by providing biobanking and laboratory services to research institutions, pharmaceutical companies, and biotechnology firms. Key revenue sources include fees from sample storage and management services, genomic analysis services, and sales of related products such as laboratory equipment and consumables. Additionally, Azenta may benefit from partnerships with academic institutions and commercial organizations that require biobanking services, which can provide steady income through long-term contracts. The company's focus on innovation and the expanding market for life sciences research also contribute to its revenue growth.

Azenta Financial Statement Overview

Summary

Azenta's financial performance is challenged by declining revenues and negative profitability margins, despite a strong balance sheet with low leverage and improving cash flow growth. Operational inefficiencies need addressing to enhance financial health.

Income Statement

Azenta's income statement shows a declining revenue trend with a negative revenue growth rate of -4.56% in the TTM period. The company is experiencing negative net profit margins, indicating profitability challenges. Gross profit margins have slightly improved to 44.92% in the TTM, but EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet indicates a strong equity position with a low debt-to-equity ratio of 0.031 in the TTM, suggesting financial stability. However, the return on equity is negative, highlighting profitability issues. The equity ratio remains robust, indicating a solid capital structure.

Cash Flow

Cash flow analysis shows a significant improvement in free cash flow growth at 76.35% in the TTM. However, the operating cash flow to net income ratio is low at 0.34, and the free cash flow to net income ratio is 0.55, indicating moderate cash generation relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	604.93M	656.32M	665.07M	555.50M	513.70M	897.27M
Gross Profit	271.73M	263.37M	263.14M	255.58M	243.81M	380.02M
EBITDA	36.22M	17.85M	55.15M	48.35M	9.94M	28.15M
Net Income	-111.59M	-164.17M	-14.26M	-11.29M	-28.87M	64.85M
Balance Sheet
Total Assets	2.02B	2.10B	2.89B	3.72B	1.82B	1.56B
Cash, Cash Equivalents and Short-Term Investments	318.86M	462.09M	1.02B	1.57B	227.51M	295.72M
Total Debt	52.63M	70.68M	60.44M	49.23M	94.77M	82.27M
Total Liabilities	345.50M	331.07M	351.22M	352.74M	494.18M	345.51M
Stockholders Equity	1.67B	1.77B	2.53B	3.36B	1.33B	1.21B
Cash Flow
Free Cash Flow	45.67M	12.90M	-21.95M	-543.48M	97.05M	-2.06M
Operating Cash Flow	83.72M	50.29M	17.49M	-466.05M	149.86M	37.87M
Investing Cash Flow	104.05M	224.74M	431.38M	1.47B	-146.35M	-22.74M
Financing Cash Flow	-257.95M	-659.21M	-844.08M	-62.76M	-25.91M	-27.02M

Azenta Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTA, the sentiment is Negative. The current price of 30.2 is below the 20-day moving average (MA) of 30.23, below the 50-day MA of 31.34, and below the 200-day MA of 37.60, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 48.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTA.

Azenta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRC	61 Neutral	$1.88B	―	-7.85%	―	16.28%	10.63%
BLFS	60 Neutral	$1.23B	―	-5.98%	―	-18.61%	92.36%
STAA	56 Neutral	$1.36B	55.81	-25.55%	―	-32.59%	-667.81%
QDEL	53 Neutral	$1.90B	―	-14.80%	―	-3.00%	76.48%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
ICUI	49 Neutral	$3.11B	―	-1.78%	―	2.95%	47.92%
AZTA	48 Neutral	$1.40B	―	-1.74%	―	-8.15%	13.50%

Azenta Corporate Events

Azenta Announces Resignation of Chief Accounting Officer

On June 27, 2025, Azenta, Inc. announced the resignation of Violetta Hughes, Vice President and Chief Accounting Officer, effective August 6, 2025. Her departure is amicable and not due to any disagreements with the company’s operations or policies, ensuring a smooth transition of responsibilities.